








AMENDMENTS TO THE CLAIMS

This Listing of Claims will replace all prior versions and listings of claims in this application.

Listing of Claims:







1. (Withdrawn) A compound, or a pharmaceutically acceptable salt thereof, selected from the group consisting of the compounds set forth in the following table:








943	
944	
945	
946	






947	
948	
949	







950	
951	
952	
953	
954	
955	
956	
957	








958	CHIRAL
959	
960	CHIRAL
961	CHIRAL
962	CHIRAL









963	 <p>chiral (+)</p>
964	<p>CHIRAL</p> 
965	<p>CHIRAL</p> 
966	<p>CHIRAL</p> 
967	<p>CHIRAL</p> 
968	




969	
970	
971	
972	
973	
974	 <p>chiral (+)</p>
975	 <p>chiral (+)</p>



976	
977	
978	 <p>chiral (-)</p>
979	 <p>chiral (+)</p>
980	

981	
982	
983	
984	
985	
986	

987	
988	
989	
990	
991	
992	
993	

994	
995	
996	
997	
998	
999	
1000	
1001	

1002	
1003	
1004	

1005	
1006	

2. (Withdrawn) A pharmaceutical formulation comprising as an active ingredient a therapeutically effective amount of a compound according to claim 1 in association with one or more pharmaceutically acceptable diluents, excipients and/or inert carriers.
3. (Withdrawn) The pharmaceutical formulation according to claim 2, for use in the prevention and/or treatment of mGluR5 receptor-mediated disorders.
4. (Withdrawn) A compound according to claim 1 for use in therapy.
5. (Withdrawn) The compound according to claim 1, for use in prevention and/or treatment of mGluR5 receptor-mediated disorders.
6. (Withdrawn) The compound according to claim 5, wherein the disorder is a neurological disorder.
7. (Withdrawn) The compound according to claim 5, wherein the disorder is a psychiatric disorder.






8. (Withdrawn) The compound according to claim 5, wherein the disorder is selected from chronic and acute pain disorders.







9. (Withdrawn) The compound according to claim 5, wherein the disorder is a gastrointestinal disorder.

10. (Withdrawn) The compound according to claim 5, wherein the disorder is selected from the group consisting of Alzheimer's disease, senile dementia, AIDS-induced dementia, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's Chorea, migraine, epilepsy, schizophrenia, depression, anxiety, acute anxiety, obsessive compulsive disorder, ophthalmological disorders, diabetic retinopathies, glaucoma, auditory neuropathic disorders, chemotherapy induced neuropathies, post-herpetic neuralgia and trigeminal neuralgia, tolerance, dependency, addiction and craving disorders, neurodevelopmental disorders, autism, mental retardation, schizophrenia, Down's Syndrome, pain related to migraine, inflammatory pain, neuropathic pain disorders, arthritis and rheumatoid diseases, low back pain, post-operative pain, pain associated with angina, renal and biliary colic, menstruation, migraine gout, stroke, head trauma, anoxic and ischemic injuries, hypoglycemia, cardiovascular diseases, GERD, and epilepsy.

11. (Withdrawn - Currently Amended) A method of manufacturing ~~The use of a compound according to claim 1 in the manufacture of a medicament for the use in the prevention and/or treatment of mGluR5 receptor-mediated disorders~~ comprising a compound according to claim 1.








12. (Currently Amended) A method of ~~prevention and/or treatment~~ of mGluR5 receptor-mediated disorders, comprising administering to a mammal in need of such ~~prevention and/or treatment~~ a therapeutically effective amount of a compound, ~~according to claim 1 or a pharmaceutically acceptable salt thereof, selected from the group consisting of the compounds set forth in the following table:~~






<u>943</u>	
<u>944</u>	
<u>945</u>	
<u>946</u>	
<u>947</u>	







<u>948</u>	
<u>949</u>	
<u>950</u>	
<u>951</u>	
<u>952</u>	
<u>953</u>	







<u>954</u>	<p>CHIRAL</p>
<u>955</u>	<p>CHIRAL</p>
<u>956</u>	<p>CHIRAL</p>
<u>957</u>	
<u>958</u>	<p>CHIRAL</p>
<u>959</u>	
<u>960</u>	<p>CHIRAL</p>








<u>961</u>	<p>CHIRAL</p>
<u>962</u>	<p>CHIRAL</p>
<u>963</u>	<p><u>chiral (+)</u></p>
<u>964</u>	<p>CHIRAL</p>
<u>965</u>	<p>CHIRAL</p>








<u>966</u>	CHIRAL 
<u>967</u>	CHIRAL 
<u>968</u>	
<u>969</u>	
<u>970</u>	
<u>971</u>	
<u>972</u>	



<u>973</u>	
<u>974</u>	 <u>chiral (+)</u>
<u>975</u>	 <u>chiral (+)</u>
<u>976</u>	CHIRAL 
<u>977</u>	CHIRAL 

<u>978</u>	 <u>chiral (-)</u>
<u>979</u>	 <u>chiral (+)</u>
<u>980</u>	
<u>981</u>	
<u>982</u>	
<u>983</u>	

<u>984</u>	
<u>985</u>	
<u>986</u>	
<u>987</u>	
<u>988</u>	
<u>989</u>	

<u>990</u>	
<u>991</u>	
<u>992</u>	
<u>993</u>	
<u>994</u>	
<u>995</u>	
<u>996</u>	

<u>997</u>	
<u>998</u>	
<u>999</u>	
<u>1000</u>	
<u>1001</u>	
<u>1002</u>	
<u>1003</u>	



wherein the disorder is selected from the group consisting of neurological disorders, psychiatric disorders, chronic and acute pain disorders, gastrointestinal disorders, Alzheimer's disease, senile dementia, AIDS-induced dementia, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's Chorea, migraine, epilepsy, schizophrenia, depression, anxiety, acute anxiety, obsessive compulsive disorder, ophthalmological disorders, diabetic retinopathies, glaucoma, auditory neuropathic disorders, chemotherapy induced neuropathies, post-herpetic neuralgia and trigeminal neuralgia, tolerance, dependency, addiction and craving disorders, neurodevelopmental disorders, autism, mental retardation, schizophrenia, Down's Syndrome, pain related to migraine, inflammatory pain, neuropathic pain disorders, arthritis and rheumatoid diseases, low back pain, post-operative pain, pain associated with angina, renal and biliary colic, menstruation, migraine gout, stroke, head trauma, anoxic and ischemic injuries, hypoglycemia, cardiovascular diseases and epilepsy.

13. (Original) The method according to claim 12, wherein the disorder is a neurological disorder.

14. (Original) The method according to claim 12, wherein the disorder is a psychiatric disorder.

15. (Original) The method according to claim 12, wherein the disorder is selected from chronic and acute pain disorders.
16. (Original) The method according to claim 12, wherein the disorder is a gastrointestinal disorder.
17. (Original) The method according to claim 12, wherein the disorder is selected from the group consisting of Alzheimer's disease, senile dementia, AIDS-induced dementia, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's Chorea, migraine, epilepsy, schizophrenia, depression, anxiety, acute anxiety, obsessive compulsive disorder, ophthalmological disorders, diabetic retinopathies, glaucoma, auditory neuropathic disorders, chemotherapy induced neuropathies, post-herpetic neuralgia and trigeminal neuralgia, tolerance, dependency, addiction and craving disorders, neurodevelopmental disorders, autism, mental retardation, schizophrenia, Down's Syndrome, pain related to migraine, inflammatory pain, neuropathic pain disorders, arthritis and rheumatoid diseases, low back pain, post-operative pain, pain associated with angina, renal and biliary colic, menstruation, migraine gout, stroke, head trauma, anoxic and ischemic injuries, hypoglycemia, cardiovascular diseases and epilepsy.
18. (Withdrawn) A method for inhibiting the activation of mGluR5 receptors, comprising treating a cell containing said receptor with an effective amount of a compound according to claim 1.